Nab-paclitaxel plus capecitabine as first-line treatment for advanced biliary tract cancers: An open-label, non-randomized, phase II clinical trial

Table 2 Treatment response in patients, n (%)

Therapeutic response assessment	Evaluable patients (n = 43)
Objective response rate (95%CI)	10 (23.26) (11.80-38.60)
Complete response	2 (4.65)
Partial response	8 (18.60)
Stable disease	20 (46.51)
Progressive disease	13 (30.23)
Disease control rate (95%CI)	30 (69.77) (53.90-82.80)
Progression-free survival (95%CI, months)	4.4 (2.5-6.3)
Overall survival (95%CI, months)	14.1 (8.3-19.9)

CI: Confidence interval.